作者
Ismail Ogulur, Yagiz Pat, Ozge Ardicli, Elena Barletta, Lacin Cevhertas, Ruben Fernandez‐Santamaria, Mengting Huang, Manal Bel Imam, Jana Koch, Siyuan Ma, Debbie J Maurer, Yasutaka Mitamura, Yaqi Peng, Urszula Radzikowska, Arturo O Rinaldi, Juan Rodriguez‐Coira, Pattraporn Satitsuksanoa, Stephan R Schneider, Alexandra Wallimann, Damir Zhakparov, Reihane Ziadlou, Marie‐Charlotte Brüggen, Willem van de Veen, Milena Sokolowska, Katja Baerenfaller, Luo Zhang, Mubeccel Akdis, Cezmi A Akdis
发表日期
2021/12
来源
Allergy
卷号
76
期号
12
页码范围
3659-3686
简介
During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network‐based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point‐of‐care systems. Ideally, samples should be collected using quick, cost‐efficient and …
学术搜索中的文章
I Ogulur, Y Pat, O Ardicli, E Barletta, L Cevhertas… - Allergy, 2021